Amgen AMGN reported fourth-quarter 2024 adjusted ... However, weakness in some key brands like Otezla is a headwind. Also, sales of Amgen’s best-selling drugs, Prolia and Xgeva, are expected ...

Amgen (NASDAQ:AMGN) did what it was "supposed to do." By that, I mean it followed through on what its chart indicated it would do in response to earnings. I'll show what I mean below, but my ...

Opinions expressed by Forbes Contributors are their own. While HON and AMGN may offer little returns in the next three years, it is helpful to see how Honeywell’s Peers fare on metrics that matter.

Investors in Amgen Inc (Symbol: AMGN) saw new options become available today, for the March 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Amgen (AMGN) ended the recent trading session at $277.88, demonstrating a +1.62% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

The “return” image in the previous section suggests that AMGN began selling off around mid-November, when Trump nominated vaccine-skeptic RFK Junior as the next secretary of the Department of ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

(see more details here) Amgen Inc. (NASDAQ:AMGN) is an innovator in human therapies ... medications Enbrel and Otezla are among the brand-name medications. The company launched its first cancer ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...